Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedFooter revision updated from v3.4.1 to v3.4.2. No changes to study details, eligibility criteria, outcomes, or participating locations.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedShow glossary feature added; the page now displays a glossary toggle. The QC status label has changed to 'Last Update Submitted that Met QC Criteria' and policy text to 'No FEAR Act Data' with a new revision tag 'v3.4.0' (replacing 'v3.3.4').SummaryDifference0.2%

- Check61 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; this is a minor site update that does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedExpanded and reorganized the Locations section to include multiple sites across the US, Australia, and Canada, with an updated revision to v3.3.3.SummaryDifference1%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.